Cardio Diagnostics Holdings (NASDAQ: CDIO) recently took the spotlight in the latest episode of the BioMedWire Podcast, with CEO and Co-Founder Dr. Meesha Dogan discussing the company's mission to improve cardiovascular disease prevention and early detection through precision medicine powered by epigenetics, genetics and artificial intelligence. The interview highlighted Cardio Diagnostics' expansion into India through partnerships with Aimil Ltd. and Dr. Lal PathLabs, as well as the company's progress through the Medicare reimbursement process, noting that CPT coding and payment steps have been completed while coverage determination remains underway.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.
The significance of this announcement lies in the growing role of AI and epigenetics in transforming cardiovascular care. Cardiovascular disease remains the leading cause of death globally, and early detection is key to improving outcomes. Cardio Diagnostics' approach using AI to integrate genetic and epigenetic data offers a more personalized risk assessment, which could lead to earlier interventions and better management of the disease. The company's expansion into India, a country with a high burden of cardiovascular disease, further underscores the potential global impact of its technology.
Moreover, the progress in Medicare reimbursement is a critical step toward making these tests accessible to a broader patient population. While the completion of CPT coding and payment steps is a positive development, the ongoing coverage determination will ultimately decide whether Medicare beneficiaries can access these tests. This could set a precedent for private insurers and influence the adoption of precision medicine in cardiology.
For more information, listeners can access the full press release here. The latest news and updates relating to CDIO are available in the company's newsroom here.
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
